VitamIN D Treating patIents With Chronic heArT failurE (VINDICATE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Despite recent advances and even when receiving optimal therapy, patients with chronic heart failure (CHF) suffer poor quality of life, with recurrent hospitalisations and persistent symptoms. The investigators have shown that patients attending the Leeds Integrated Heart Failure Service are also frequently deficient in vitamin D and that the severity of the deficiency relates to the levels of symptoms, exercise capacity, diuretic requirements and response to optimal medical therapy. Vitamin D contributes to cardiac and skeletal muscle contractile function, immune function, pancreatic insulin release, and neuro-hormonal homeostasis. A randomised, placebo-controlled proof of concept study in 60 CHF patients has demonstrated improvements in submaximal exercise capacity and symptoms. VINDICATE will be a randomised, placebo-controlled developmental clinical study in 250 patients with CHF and vitamin D deficiency. The present study is designed to detect whether vitamin D has pathophysiologically important effects, as well as providing preliminary evidence of efficacy and safety by examining cardiac function (using cardiac magnetic resonance imaging) and submaximal exercise capacity (by 6-minute walk test). This will provide pertinent data to inform a larger multi-centre efficacy and effectiveness study.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Heart Failure |
Dietary Supplement: Vitamin D |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | VitamIN D Treating patIents With Chronic heArT failurE |
- 6 minute walk distance [ Time Frame: After one year ] [ Designated as safety issue: No ]
- Left ventricular function by Cardiac Magnetic Resonance [ Time Frame: At one year ] [ Designated as safety issue: No ]
- Peak exercise capacity [ Time Frame: At one year ] [ Designated as safety issue: No ]
- Biochemical changes [ Time Frame: At one year (but also throughout) ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 250 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Vitamin D
Vitamin D 100mcg per day
|
Dietary Supplement: Vitamin D
100mcg per day
|
|
Placebo Comparator: Placebo
Standard optimal therapy
|
Dietary Supplement: Vitamin D
100mcg per day
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Class II or III CHF
- Stable symptoms (on otherwise optimally tolerated medical therapy)
- Able to give written informed consent
Exclusion Criteria:
- Currently taking vitamin D supplementation
- Untreated valvular heart disease
- Existing class I indication for vitamin D therapy
- History of primary hyperparathyroidism, tuberculosis, sarcoidosis, malignancy or hypercalcaemia
- Heart failure due to anaemia or thyrotoxicosis
- Renal failure (GFR <30l/min)
Contacts and Locations| Contact: Klaus K Witte, MD | k.k.witte@leeds.ac.uk |
| United Kingdom | |
| Hull University | Active, not recruiting |
| Kingston-upon-Hull, United Kingdom, HU1 | |
| Leeds General Infirmary | Recruiting |
| Leeds, United Kingdom, LS1 3EX | |
| Principal Investigator: Klaus K Witte, MD | |
| Principal Investigator: | Klaus K Witte, MD | University of Leeds |
More Information
No publications provided
| Responsible Party: | KK Witte, Senior Lecturer in Cardiology, University of Leeds |
| ClinicalTrials.gov Identifier: | NCT01619891 History of Changes |
| Other Study ID Numbers: | MR/J00281X/1 |
| Study First Received: | June 12, 2012 |
| Last Updated: | March 24, 2013 |
| Health Authority: | United Kingdom: National Health Service |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases Vitamin D Ergocalciferols Vitamins |
Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 16, 2013